GF Fund Management CO. LTD. Invests $3.71 Million in Pfizer Inc. (NYSE:PFE)

GF Fund Management CO. LTD. purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 139,762 shares of the biopharmaceutical company's stock, valued at approximately $3,708,000.

A number of other hedge funds have also recently bought and sold shares of the business. Pinney & Scofield Inc. purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $141,000. WCG Wealth Advisors LLC raised its holdings in Pfizer by 2.1% in the fourth quarter. WCG Wealth Advisors LLC now owns 56,107 shares of the biopharmaceutical company's stock valued at $1,489,000 after acquiring an additional 1,151 shares in the last quarter. Pacific Point Advisors LLC bought a new position in Pfizer during the 4th quarter valued at $608,000. Neo Ivy Capital Management grew its holdings in Pfizer by 82.0% during the 4th quarter. Neo Ivy Capital Management now owns 140,457 shares of the biopharmaceutical company's stock worth $3,726,000 after acquiring an additional 63,289 shares in the last quarter. Finally, Sunbelt Securities Inc. increased its position in shares of Pfizer by 19.0% in the 4th quarter. Sunbelt Securities Inc. now owns 71,237 shares of the biopharmaceutical company's stock worth $1,882,000 after purchasing an additional 11,391 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PFE. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 1.3%

Pfizer stock opened at $23.33 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $132.66 billion, a price-to-earnings ratio of 16.55, a PEG ratio of 0.64 and a beta of 0.58. The firm has a 50-day moving average price of $23.38 and a two-hundred day moving average price of $25.17.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. The business's revenue was down 7.8% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.37%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.